Moroctocog Alfa (AF-CC) for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Patients with Hemophilia A in India

[1]  E. Santagostino,et al.  WFH Guidelines for the Management of Hemophilia, 3rd edition , 2020, Haemophilia : the official journal of the World Federation of Hemophilia.

[2]  V. Calafiore,et al.  Status of Recombinant Factor VIII Concentrate Treatment for Hemophilia A in Italy: Characteristics and Clinical Benefits , 2019, Front. Med..

[3]  L. Tang,et al.  Impact of prophylaxis on health‐related quality of life of boys with hemophilia: An analysis of pooled data from 9 countries , 2019, Research and practice in thrombosis and haemostasis.

[4]  K. Lieuw.  Many factor VIII products available in the treatment of hemophilia A: an embarrassment of riches? , 2017, Journal of blood medicine.

[5]  Sheh-Li Chen.  Economic costs of hemophilia and the impact of prophylactic treatment on patient management. , 2016, The American journal of managed care.

[6]  J. Astermark,et al.  Lifelong prophylaxis in a large cohort of adult patients with severe haemophilia: a beneficial effect on orthopaedic outcome and quality of life , 2012, European journal of haematology.

[7]  S. Phadke.  Hemophilia Care in India: A Review and Experience from a Tertiary Care Centre in Uttar Pradesh , 2011, Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion.

[8]  P. Mannucci,et al.  Clinical evaluation of moroctocog alfa (AF‐CC), a new generation of B‐domain deleted recombinant factor VIII (BDDrFVIII) for treatment of haemophilia A: demonstration of safety, efficacy, and pharmacokinetic equivalence to full‐length recombinant factor VIII , 2009, Haemophilia : the official journal of the World Federation of Hemophilia.

[9]  N. von Hentig,et al.  A review of current literature on second-generation, sucrose-formulated, full-length recombinant factor VIII. , 2009, Drugs of today.